NCCN Work Group Report: Emerging Issues in Tissue Allocation

Author: Jessica K. DeMartino PhD
View More View Less
Restricted access

Expanding research interests in molecular profiling over the past several years have led researchers in academia and pharmaceutical and biotechnology companies to significantly increase their need for access to tissue specimens collected through clinical care and clinical trials. As a result, tissue allocation has become a growing issue for many clinical and translational investigators. High-quality biospecimens are needed by all stakeholders in order to have scientifically accurate studies and results. At the center of the process are the patients, who have increasingly become active partners in the clinical research enterprise as individuals and through highly sophisticated patient advocacy organizations. All stakeholders must recognize that human specimens, including tissue, represent a valuable and unique resource that must have proper acquisition, handling, custodianship, and consent for use in accordance with best practices for biospecimen resources.

  • 1.

    Moore HM, Kelly A, Jewell SD. Biospecimen reporting for improved study quality. Biopreserv Biobank 2011;9:5770.

  • 2.

    Gerlinger M, Rowan AJ, Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883892.

    • Search Google Scholar
    • Export Citation
  • 3.

    Informed Consent for Genomics Research. Available at: https://www.genome.gov/27026588. Accessed August 21, 2015.

  • 4.

    Mello MM, Wolf LE. The Havasupai indian tribe case – lessons for research involving stored biologic samples. N Engl J Med 2010;363:204207.

    • Search Google Scholar
    • Export Citation
  • 5.

    Federal Register, Federal Policy for the Projection of Human Subjects. Available at: http://www.gpo.gov/fdsys/pkg/FR-2015-09-08/pdf/2015-21756.pdf. Accessed September 17, 2015.

    • Search Google Scholar
    • Export Citation
  • 6.

    Biorepositories and Biospecimens Research Branch, Mission and Goals. Available at: http://biospecimens.cancer.gov/about/overview.asp. Accessed August 20, 2015.

    • Search Google Scholar
    • Export Citation
  • 7.

    Biorepository Coordinating Committee. Available at: http://biospecimens.cancer.gov/about/bcc.asp. Accessed August 20, 2015.

  • 8.

    Biospecimen Research Network. Available at: http://biospecimens.cancer.gov/researchnetwork/default.asp Accessed August 20, 2015.

  • 9.

    Biospecimen Pre-analytics Variable Program. Available at: http://biospecimens.cancer.gov/programs/bpv/default.asp. Accessed August 20, 2015.

    • Search Google Scholar
    • Export Citation
  • 10.

    The Biospecimen Research Database. Available at: https://brd.nci.nih.gov/brd/. Accessed August 20, 2015.

  • 11.

    Eiseman E. Effects of preanalytical variables on the quality of biospecimens used to study genetic changes in cancer. RAND Corporation 2009. Available: http://www.rand.org/pubs/documented_briefings/DB572.html. Accessed August 20, 2015.

    • Search Google Scholar
    • Export Citation
  • 12.

    Hammond ME, Hayes DF, Dowsett M. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907922.

    • Search Google Scholar
    • Export Citation
  • 13.

    Wolff AC, Hammond ME, Hicks DG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:39974013.

    • Search Google Scholar
    • Export Citation
  • 14.

    Khoury T, Sait S, Hwang H. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:14571467.

  • 15.

    Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 2012;25:10981105.

    • Search Google Scholar
    • Export Citation
  • 16.

    Neumeister VM, Anagnostou V, Siddiqui S. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 2012;104:18151824.

    • Search Google Scholar
    • Export Citation
  • 17.

    Vassilakopoulou M, Parisi F, Siddiqui S. Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Lab Invest 2015;95:334341.

    • Search Google Scholar
    • Export Citation
  • 18.

    Neumeister VM, Parisi F, England AM. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Lab Invest 2014;94:467474.

    • Search Google Scholar
    • Export Citation
  • 19.

    The National Biomarker Development Alliance Convergence Conferences. Available at: http://nbdabiomarkers.org/projects-standards-and-guidelines/consensus-conferences. Accessed August 20, 2015.

    • Search Google Scholar
    • Export Citation
  • 20.

    Rimm DL, Nielsen TO, Jewell SD. Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol 2011;29:22822290.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 541 381 7
PDF Downloads 28 20 6
EPUB Downloads 0 0 0